Claritev Corporation

NYSE:CTEV

Medical - Healthcare Information Services

Healthcare
$22.30 +1.41%

+$0.42 today

Market cap
$380.77M
Beta
0.77
P/E (TTM)
-1.8
EPS (TTM)
-$17.16
52W Low $11.50High $74.07

Volume 0.31M

Average 0.14M

CTEV EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Claritev CorporationNYSE: CTEV

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $116.82M rose 3.1% year over year, behind the +198.9% change in trailing-twelve-month EBITDA. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +44.3% a year.

Context

  • EBITDA amounted to 49.2% of revenue in FY2025, down 59.1 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $492.61M (+3.6%) for the fiscal year ending Dec 2026, a slowdown from the +147.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$116.82M+11.5% QoQ
Last fiscal yearDec 2025
$475.44M+147.2% YoY
LTMMar 2026
$517.45M+198.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.1%+9.4%+6.3 pp
1 year+147.2%+3.6%-143.6 pp
3-year CAGR+44.3%-2.3%-46.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
475.44M USD
Year-over-year change
+147.2%
4-year CAGR
-12.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CTEV compares with its peers on the latest reported figures

  • CTEV's LTM Mar 2026 EBITDA of $517.45M is the highest of the 11 companies compared; the peer median is -$25.38M.
  • Its year-over-year change of +198.9% is the highest of 11, against a peer median of -74.9%.
  • EBITDA amounts to 52.9% of revenue for CTEV, versus a peer median of 17.6%.
CTEV Competitors Peer median
EBITDA for CTEV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CTEVClaritev CorporationLTM Mar 2026$517.45M +198.9%+44.3%52.9%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$173.34M +1.2%+41.4%22.0%
INMDInMode Ltd.LTM Mar 2026$102.9M -26.8%-18.1%27.5%
IRMDIRadimed CorporationLTM Mar 2026$32.23M +25.1%+22.2%37.4%
LFMDLifeMD, Inc.LTM Mar 2026-$4.22M -227.5%—1.9%
AXGNAxoGen, Inc.LTM Sep 2026-$21.24M -198.3%—8.0%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.53M +74.2%—1550.9%
OPKOPKO Health, Inc.LTM Mar 2026-$34.69M -123.1%—6.0%
SANASana Biotechnology, Inc.LTM Mar 2026-$187.06M +2.3%——
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-$289.3M -260.5%—17.6%
EVHEvolent Health, Inc.LTM Mar 2026-$314.51M -1056.6%—16.7%
Peer median (excluding CTEV) -$25.38M-74.9%+22.2%17.6%

Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12B1.08B961.52M930.62M965.41M
Cost of Revenue175.29M204.1M235.47M239.4M698.84M
Gross Profit942.31M875.62M726.06M691.22M266.58M
Gross Margin84.3%81.1%75.5%74.3%27.6%
Research & Development00000
Selling, General & Admin151.1M132.14M135.99M160.22M221.52M
Operating Expenses556.19M1.24B564.07M2.08B221.52M
Depreciation & Amortization412.06M415.66M425.79M436.44M448.45M
EBITDA814.99M158.32M651.93M(1.01B)475.44M
EBITDA Margin72.9%14.7%67.8%-108.3%49.2%
Operating Income386.12M(362.73M)161.98M(1.39B)45.06M
Operating Margin34.5%-33.6%16.8%-149.4%4.7%
Interest Income30K3.5M8.23M3.13M1.56M
Interest Expense267.48M303.4M333.21M326.37M400.07M
Other Income / Expenses(250.67M)(198.01M)(269.04M)(380.78M)(418.14M)
Income Before Tax135.45M(560.74M)(107.06M)(1.77B)(373.08M)
Pre-Tax Margin12.1%-51.9%-11.1%-190.3%-38.6%
Income Tax Expense33.37M12.17M(15.36M)(124.88M)(88.8M)
Net Income102.08M(572.91M)(91.7M)(1.65B)(284.28M)
Net Margin9.1%-53.1%-9.5%-176.9%-29.4%
EPS (Basic)6.40(35.87)(5.69)(101.92)(17.30)
EPS (Diluted)6.40(35.87)(5.69)(101.92)(17.30)
Weighted Avg Shares16.28M15.97M16.13M16.15M16.43M
Weighted Avg Shares (Diluted)16.29M15.97M16.13M16.15M16.43M

Claritev Corporation

NYSE:CTEV

Intrinsic Alpha fair value

Locked

Current Price

$22.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.